Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander
- None.
- None.
Insights
The introduction of the Motiva Flora® SmoothSilk® Tissue Expander represents a significant innovation in the field of breast reconstruction, especially for breast cancer patients. Its patented SmoothSilk® surface technology has been scientifically shown to produce less inflammation and foreign body response, which are critical factors in the success of reconstructive surgeries. The absence of magnets in the device, which makes it MR conditional, addresses a common issue with existing tissue expanders that contain magnets and interfere with MRI diagnostics and radiation therapy. This technological advancement could potentially lead to improved patient outcomes by enhancing the precision of oncology treatments and reducing post-surgical complications.
Establishment Labs Holdings Inc.'s FDA clearance and subsequent first use of the Motiva Flora® in the United States is a strategic milestone for the company, positioning it within the lucrative U.S. breast reconstruction market. As the largest market for breast reconstruction, the U.S. represents a significant commercial opportunity for Establishment Labs. The company's core principle of improving women's health aligns with the growing demand for patient-centered innovations in medical technology. The long-term success of the product will depend on its adoption by surgeons, patient satisfaction and the demonstration of superior outcomes compared to existing alternatives. The market will closely monitor the impact of this product launch on Establishment Labs' financial performance and market share.
From a clinical perspective, the introduction of the Motiva Flora® Tissue Expander is a notable advancement in the field of plastic and reconstructive surgery. The device's MR conditional status and non-magnetic port design offer a new level of compatibility with imaging and radiation therapy, which are integral components of cancer treatment and post-operative care. This could translate into more seamless integration of reconstructive surgery into the overall cancer care pathway, potentially reducing the number of procedures patients need to undergo and improving aesthetic outcomes. The RFID-enabled port also suggests enhanced operability and patient safety, which are paramount in reconstructive procedures.
"This Flora device is a new resource in our toolkit for breast cancer reconstruction,” Dr. Clemens noted. “It introduces features such as being MR conditional and also reduces interference during radiation therapy. It's essential for patients to have access to innovative solutions that may improve their treatment outcomes and facilitate their journey of restoration."
The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces1. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. All other commercially available breast tissue expanders include magnets.
“We are so pleased to enter
- Doloff, J.C., Veiseh, O., de Mezerville, R. et al. The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. Nat Biomed Eng 5, 1115–1130 (2021). https://doi.org/10.1038/s41551-021-00739-4
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness through the power of science, engineering, and technology. The Company offers a portfolio of Femtech solutions for breast health, breast aesthetics and breast reconstruction. The over three million Motiva® devices Establishment Labs has delivered to plastic and reconstructive surgeons since 2010 have created a new standard for safety and patient satisfaction in the over 85 countries in which they are available. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and it is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MR conditional. Mia Femtech™, Establishment Lab’s unique minimally invasive experience for breast harmony, is the Company’s most recent breakthrough innovation. These solutions are supported by over 200 patent applications in 25 separate patent families worldwide and over 50 scientific studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
Establishment Labs' Motiva silicone gel-filled implants are currently not approved for commercial distribution in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can find many (but not all) of these statements by looking for words such as “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “intends to,” “would,” “will,” “may” or other similar expressions in this press release. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, including related product development and commercialization and regulatory approvals, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company’s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. These and other factors that could cause or contribute to actual results differing materially from our expectations include, among others, those risks and uncertainties discussed in the company’s annual report on Form 10-K filed on March 1, 2023 and discussed in the company's quarterly report on Form 10-Q filed on November 8, 2023, which risks and uncertainties may be updated in the future in other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102192117/en/
Investor/Media Contact:
Raj Denhoy
415-828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
What is the name of the medical technology company mentioned in the press release?
What is the ticker symbol of Establishment Labs Holdings Inc.?
Where was the Motiva Flora® SmoothSilk® Tissue Expander used for the first time in the United States?
What are some of the proprietary innovations of the Flora® Tissue Expander?
What are the benefits of the SmoothSilk® surface technology?
Who is the Founder and CEO of Establishment Labs?
What did Juan José Chacón-Quirós emphasize in relation to the company's commitment?
